← Back to Clinical Trials
Recruiting NCT07352215

NCT07352215 PRP Plus Fractional CO₂ Laser for Acne Scars

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07352215
Status Recruiting
Phase
Sponsor Gujranwala medical college District Headquarters Hospital, Gujranwala
Condition Post-Acne Atrophic Scars
Study Type INTERVENTIONAL
Enrollment 70 participants
Start Date 2025-10-31
Primary Completion 2026-01-12

Trial Parameters

Condition Post-Acne Atrophic Scars
Sponsor Gujranwala medical college District Headquarters Hospital, Gujranwala
Study Type INTERVENTIONAL
Phase N/A
Enrollment 70
Sex ALL
Min Age 18 Years
Max Age 40 Years
Start Date 2025-10-31
Completion 2026-01-12
Interventions
Fractional CO₂ Laser + Platelet-Rich Plasma (PRP)Fractional CO₂ Laser Only

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

Brief Summary

This randomized controlled trial aims to evaluate whether adding platelet-rich plasma (PRP) to fractional CO₂ laser resurfacing improves the treatment of moderate-to-severe acne scars compared with laser alone. Seventy adults aged 18-40 years will be recruited from the Dermatology Department of Gujranwala Medical College Teaching Hospital. Participants will be randomly assigned to receive either fractional CO₂ laser combined with topical PRP or fractional CO₂ laser alone, with three treatment sessions delivered four weeks apart. The primary outcome is the change in acne scar severity measured using the Goodman and Baron Quantitative Acne Scar Scale. Secondary outcomes include redness, edema, pain scores, and patient satisfaction assessed using Likert and numeric rating scales. The study is single-blinded, with patients unaware of treatment allocation. PRP will be prepared using a standardized double-spin centrifugation process. Data will be analyzed using appropriate statistical tests with a significance level of p \< 0.05. The study aims to determine whether PRP enhances laser efficacy, reduces side effects, and improves patient-reported outcomes.

Eligibility Criteria

Inclusion Criteria:Adults aged 18 to 40 years Male and female participants Fitzpatrick skin types I to V Presence of moderate-to-severe acne scars Willing to undergo 3 treatment sessions and follow-up visits Able to provide informed consent - Exclusion Criteria:Use of topical anti-acne medications in the past 1 month History of keloid formation or hypertrophic scarring Active acne or active skin inflammation at treatment area Diabetes mellitus Photosensitive disorders (e.g., lupus, dermatomyositis) Melasma Active infections (e.g., Herpes simplex) Recent laser resurfacing or similar procedures Outdoor workers with high sun exposure Vitiligo Pregnancy or breastfeeding Bleeding disorders or anticoagulant therapy Unrealistic expectations or inability to comply with follow-up \-

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology